Lebrikizumab gets the nod for treating moderate-to-severe atopic dermatitis in Europe

Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.
MDedge News

source https://www.medscape.com/s/viewarticle/998647?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?